PMC9359098_01
Case 1 : A 71-year-old woman with PB-DLBCL. (A) swelling of the right upper extremity. (B) bruising and skin ecchymoses on the right upper extremity and the right anterior chest wall. (C) The time line of this patient.
fonc-12-941633-g001.jpg
PMC9359098_01_fonc-12-941633-g001.jpg
f1
No similar dermatological toxicities occurred again during any of these periods (Figure 1).
PMC9359098_02
Case 2 : A 56-year-old man with CLL. (A, C, D) difused and severe maculopapular rash with purpuric lesions on the trunk, upper extremity and lower extremity. (B) necrotizing folliculitis with suspected Staphylococcus aureus superinfection on the back. (E) The time line of this patient.
fonc-12-941633-g002.jpg
PMC9359098_02_fonc-12-941633-g002.jpg
f2
The patient is currently in the follow-up phase and the generalized rash has significantly subsided and improved, but the patient refused to continue the treatment of zanubrutinib (Figure 2).
PMC9359098_03
Case 3 : A 69-year-old man with CLL. (A) cutaneous ecchymosis with central necrosis. (B) pustules on the left lower extremity. (C) The time line of this patient.
fonc-12-941633-g003.jpg
PMC9359098_03_fonc-12-941633-g003.jpg
f3
On our advice, the patient was reintroduced to oral zanubrutinib in October 2021, after which the patient did not experience similar dermatological toxicities (Figure 3).